• A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis 

      Vincenti, Flavio; Fervenza, Fernando Custodio; Campbell, Kirk Nicholas; Díaz, Montserrat M.; Gesualdo, Loreto; Nelson, Peter; Praga, Manuel; Radhakrishnan, Jai; Sellin, Lorenz K.; Singh, Ajay; Thornley-Brown, Denyse P.; Veronese, Francisco José Veríssimo; Accomando, Beverly; Engstrand, Sara; Ledbetter, Steven R.; Lin, Julie; Neylan, John F.; Tumlin, James A.; Focal Segmental Glomerulosclerosis Study Group (2017) [Artigo de periódico]
      Introduction: Steroid-resistant focal segmental glomerulosclerosis (SR-FSGS) is a common glomerulopathy associated with nephrotic range proteinuria. Treatment goals are reduction in proteinuria, which can delay end-stage ...